ストックスクリーナーアプリを入手
0.272
2.54%
-0.0071
前日終値:
$0.2791
開ける：
$0.2707
24時間の取引高:
72,014
Relative Volume:
0.36
時価総額：
$10.62M
収益：
-
当期純損益:
$-117.67M
株価収益率:
-0.088
EPS:
-3.09
ネットキャッシュフロー:
$-101.06M
1週間 パフォーマンス:
+6.96%
1か月 パフォーマンス:
+18.78%
6か月 パフォーマンス:
-59.41%
1年 パフォーマンス:
-89.96%
1日の値動き範囲:
$0.2707
$0.2899
1週間の範囲:
$0.2515
$0.2997
52週間の値動き範囲:
$0.2195
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
名前
Athira Pharma Inc
セクター
電話
(425) 620-8501
住所
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
ATHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.272 | 9.93M | 0 | -117.67M | -101.06M | -3.09 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-04 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-09-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 開始されました | Rodman & Renshaw | Buy |
| 2022-10-17 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | ダウングレード | Jefferies | Buy → Hold |
| 2022-06-23 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | 開始されました | BTIG Research | Buy |
| 2022-04-21 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Goldman | Neutral |
| 2020-10-13 | 開始されました | Goldman | Buy |
| 2020-10-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-13 | 開始されました | Jefferies | Buy |
| 2020-10-13 | 開始されました | Stifel | Buy |
すべてを表示
Athira Pharma Inc (ATHA) 最新ニュース
Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance
Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World
Athira Pharma Reports Reduced Losses and Strategic Focus - MSN
Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus
Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times
Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com India
Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 - Investing.com Australia
Athira Pharma stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
SEC Form PRE 14A filed by Athira Pharma Inc. - Quantisnow
Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa
What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News
Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks
Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks
Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN
Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire
Athira Pharma, Inc. SEC 10-K Report - TradingView
Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia
Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
Can This Former Amgen VP Transform Terns Pharmaceuticals as New CFO? - Stock Titan
ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com
Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World
Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World
Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha
Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN
Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St
Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review
Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews
Athira Pharma Inc (ATHA) 財務データ
収益
当期純利益
現金流量
EPS
Athira Pharma Inc (ATHA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '25 |
Sale |
0.56 |
10,826 |
6,083 |
35,841 |
| Litton Mark James | President and CEO |
Dec 31 '24 |
Option Exercise |
0.00 |
108,333 |
0 |
267,698 |
| Litton Mark James | President and CEO |
Jan 02 '25 |
Sale |
0.56 |
25,107 |
14,108 |
242,591 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
139,271 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
130,761 |
| Renninger Robert | VP of Finance |
Dec 31 '24 |
Option Exercise |
0.00 |
12,359 |
0 |
92,605 |
| Renninger Robert | VP of Finance |
Jan 02 '25 |
Sale |
0.56 |
2,881 |
1,619 |
89,724 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
92,245 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
83,735 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):